On January 12, 2025 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation at the 43rd Annual J.P. Morgan Healthcare Conference and provided 2025 corporate guidance and program updates (Press release, Ideaya Biosciences, JAN 12, 2025, View Source [SID1234649622]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
43rd Annual J.P. Morgan Healthcare Conference
Monday, January 13th, 2025, at 5:15 PM PT (8:15 PM ET)
Presentation by Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan
2025 Corporate Guidance to be Presented at the 43rd Annual J.P. Morgan Healthcare Conference:
Corporate financial guidance
$1.2 billion of cash, cash equivalents and marketable securities as of September 30, 2024, is anticipated to fund operations into at least 2028
Darovasertib, a potential first-in-class Phase 2/3 PKC inhibitor program targeting Metastatic Uveal Melanoma (MUM) and Uveal Melanoma (UM)
Median progression free survival readout for potential Phase 2/3 registration-enabling trial of the darovasertib and crizotinib combination in first-line (1L) patients with HLA-A2-negative MUM targeted by year-end 2025, pending enrollment status and data maturity. Enrollment has exceeded over 200 patients as of January 6, 2025
Phase 2 1L MUM median overall survival readout for the darovasertib and crizotinib combination in approximately 38 1L MUM patients targeted in 2025
Targeting Phase 2 neoadjuvant UM clinical data update for darovasertib in over 75 patients and a regulatory update in 2025
Initiation of the Phase 3 registration-enabling trial for darovasertib in neoadjuvant UM is planned for the first half of 2025
IDE397, a potential first-in-class Phase 2 MAT2A Inhibitor program targeting MTAP-deletion solid tumors
Clinical program update(s) for Phase 1/2 study of IDE397 in combination with Trodelvy in MTAP-deletion urothelial cancer (UC) in 2025
Target to enable wholly owned IDE397 + IDE892 (IDEAYA PRMT5) clinical combination in the second half of 2025 to target MTAP-deletion non-small cell lung cancer (NSCLC)
IDE849 (SHR-4849), a potential first-in-class Phase 1 DLL3 TOP1i ADC targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs)
Clinical program update(s) targeted in 2025
Updated IDE849 clinical program slides have been provided in the JPM 2025 corporate presentation, including preclinical product profile, CT-scan tumor size waterfall plot by RECIST 1.1, and SCLC patient case study
IDE275 (GSK959), a potential first-in-class Phase 1 Werner Helicase program targeting MSI-high solid tumors
Targeting presentation at a medical conference with GSK, highlighting IDE275’s differentiated potential best-in-class profile, in the first half of 2025
IDE161, a potential first-in-class Phase 1 PARG inhibitor program targeting solid tumors
Targeting Phase 1 expansion of IDE161 in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in MSI-high and MSS endometrial cancer in 2025
Targeting clinical combination(s) of IDE161 with Topo-ADCs in 2025
IDE705 (GSK101), a potential first-in-class Phase 1 Pol Theta Helicase Inhibitor targeting homologous recombination deficiency (HRD) solid tumors
Targeting Phase 2 expansion in HRD solid tumors, enabling a potential $10 million milestone payment from GSK
3 IND-filings targeted in 2025, representing IDEAYA’s 7th, 8th, and 9th potential clinical stage precision medicine oncology program targeting solid tumors
IDE892, a potential best-in-class MTA-cooperative PRMT5 inhibitor, in mid-year 2025. Combination potential with IDE397
IDE034, a potential first-in-class B7H3/PTK7 TOP1i bispecific ADC, in the second half of 2025. Combination potential with IDE161
IDE251, a potential first-in-class KAT6/7 dual inhibitor development candidate, in the second half of 2025. Combination potential with multiple programs in IDEAYA’s pipeline
IDEAYA’s updated JPM 2025 corporate presentation reflecting its 2025 corporate guidance is available on its website under the Investor Relations section: View Source
A live audio webcast of the presentation and Q&A session will be available under the "Investors/Events" section of the IDEAYA website at View Source and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.